Dishman Carbogen Amcis Limited (DCAL.NS)
INR 210.31
(1.37%)
INR 210.31
(1.37%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 3.07 Billion INR | -20.41% |
| 2022 | 3.07 Billion INR | 1.58% |
| 2021 | 3.51 Billion INR | 15.45% |
| 2020 | 2.86 Billion INR | -45.24% |
| 2019 | 5.42 Billion INR | -4.66% |
| 2018 | 5.97 Billion INR | 21.65% |
| 2017 | 4.9 Billion INR | 2.33% |
| 2016 | 4.78 Billion INR | 15.59% |
| 2015 | 4.36 Billion INR | 5.09% |
| 2014 | 3.99 Billion INR | 14.25% |
| 2013 | 3.57 Billion INR | 13.29% |
| 2012 | 3.07 Billion INR | 21.74% |
| 2011 | 2.34 Billion INR | 21.87% |
| 2010 | 2.16 Billion INR | -0.76% |
| 2009 | 2.3 Billion INR | -22.05% |
| 2008 | 2.61 Billion INR | 80.83% |
| 2007 | 1.52 Billion INR | 26.46% |
| 2006 | 1.15 Billion INR | 76.02% |
| 2005 | 649.75 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 235.3 Million INR | -62.61% |
| 2023 Q2 | 693.2 Million INR | -46.01% |
| 2023 Q1 | 1.28 Billion INR | 120.64% |
| 2023 FY | - INR | -20.41% |
| 2023 Q4 | 626.8 Million INR | -46.65% |
| 2023 Q3 | 1.17 Billion INR | 69.47% |
| 2022 FY | - INR | 1.58% |
| 2022 Q1 | 939.6 Million INR | 1481.82% |
| 2022 Q2 | 874.5 Million INR | -6.93% |
| 2022 Q4 | 581.9 Million INR | -51.66% |
| 2022 Q3 | 1.2 Billion INR | 37.64% |
| 2021 Q4 | 59.4 Million INR | -95.38% |
| 2021 FY | - INR | 15.45% |
| 2021 Q2 | 1.08 Billion INR | -2.0% |
| 2021 Q1 | 1.11 Billion INR | 74.36% |
| 2021 Q3 | 1.28 Billion INR | 18.11% |
| 2020 FY | - INR | -45.24% |
| 2020 Q4 | 636.9 Million INR | -11.0% |
| 2020 Q3 | 715.6 Million INR | -24.67% |
| 2020 Q2 | 949.9 Million INR | 83.45% |
| 2020 Q1 | 517.8 Million INR | -64.69% |
| 2019 Q1 | 1.27 Billion INR | -25.74% |
| 2019 FY | - INR | -4.66% |
| 2019 Q2 | 1.52 Billion INR | 19.75% |
| 2019 Q4 | 1.46 Billion INR | 9.28% |
| 2019 Q3 | 1.34 Billion INR | -11.93% |
| 2018 Q3 | 1.46 Billion INR | 1.76% |
| 2018 Q2 | 1.43 Billion INR | 13.17% |
| 2018 Q1 | 1.26 Billion INR | -7.15% |
| 2018 Q4 | 1.71 Billion INR | 17.27% |
| 2018 FY | - INR | 21.65% |
| 2017 Q4 | 1.36 Billion INR | 0.6% |
| 2017 FY | - INR | 2.33% |
| 2017 Q3 | 1.35 Billion INR | -4.35% |
| 2017 Q2 | 1.42 Billion INR | 85.43% |
| 2017 Q1 | 765.8 Million INR | -48.95% |
| 2016 Q1 | 1.09 Billion INR | -1.54% |
| 2016 Q2 | 1.23 Billion INR | 13.04% |
| 2016 Q4 | 1.5 Billion INR | 56.76% |
| 2016 Q3 | 956.9 Million INR | -22.47% |
| 2016 FY | - INR | 15.59% |
| 2015 Q3 | 1.11 Billion INR | 12.67% |
| 2015 Q4 | 1.1 Billion INR | -0.68% |
| 2015 FY | - INR | 5.09% |
| 2015 Q1 | 1.08 Billion INR | -21.14% |
| 2015 Q2 | 991.09 Million INR | -8.69% |
| 2014 Q4 | 1.37 Billion INR | 68.47% |
| 2014 Q3 | 817.06 Million INR | -7.98% |
| 2014 Q1 | 798.87 Million INR | -4.02% |
| 2014 Q2 | 887.96 Million INR | 11.15% |
| 2014 FY | - INR | 14.25% |
| 2013 Q4 | 832.32 Million INR | 25.15% |
| 2013 Q3 | 665.06 Million INR | -32.7% |
| 2013 Q2 | 988.2 Million INR | 13.45% |
| 2013 Q1 | 871.07 Million INR | 11.06% |
| 2013 FY | - INR | 13.29% |
| 2012 Q3 | 683.75 Million INR | 1.58% |
| 2012 Q4 | 784.29 Million INR | 14.7% |
| 2012 Q1 | 862.34 Million INR | -14.86% |
| 2012 FY | - INR | 21.74% |
| 2012 Q2 | 673.11 Million INR | -21.94% |
| 2011 Q4 | 1.01 Billion INR | 102.62% |
| 2011 Q3 | 499.87 Million INR | 0.0% |
| 2011 FY | - INR | 21.87% |
| 2010 FY | - INR | -0.76% |
| 2009 FY | - INR | -22.05% |
| 2008 FY | - INR | 80.83% |
| 2007 FY | - INR | 26.46% |
| 2006 FY | - INR | 76.02% |
| 2005 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Biocon Limited | 41.52 Billion INR | 92.603% |
| Blue Jet Healthcare Limited | 2.29 Billion INR | -34.005% |
| Concord Biotech Limited | 4.65 Billion INR | 34.069% |
| Jubilant Ingrevia Limited | 4.56 Billion INR | 32.698% |
| Lyka Labs Limited | 167.58 Million INR | -1732.937% |
| Panacea Biotec Limited | -47.58 Million INR | 6556.074% |
| Piramal Pharma Limited | 13.05 Billion INR | 76.471% |
| SMS Lifesciences India Limited | 349.41 Million INR | -779.139% |
| Supriya Lifescience Limited | 1.83 Billion INR | -67.331% |
| Syngene International Limited | 10.84 Billion INR | 71.681% |
| TAKE Solutions Limited | -1.05 Billion INR | 392.319% |
| Zota Health Care Limited | 82.07 Million INR | -3642.766% |